South Korean health tech company Neurophet has obtained certification from Singapore’s Health Sciences Authority for its AI-enabled degenerative brain disease diagnosis assistant software. The company seeks to enter the highly-valuable Singaporean medical industry forecasted to grow to about $49 billion by 2029.

Singapore has given the green light to Neurophet’s groundbreaking AI technology that detects and analyzes brain degeneration. With the growing incidence of dementia and related disorders, this powerful brain imaging software offers new hope for early diagnosis and treatment. Approved by the Singapore Ministry of Health, Neurophet’s AI brain degeneration analysis software promises to revolutionize the field of neuroscience and transform the lives of millions of people worldwide. In this article, we explore the innovative technology behind Neurophet’s software and the potential impact it could have on brain disorder detection and treatment.


South Korean health tech firm Neurophet has secured accreditation from Singapore’s Health Sciences Authority for its AI-enhanced software that assists with the diagnosis of degenerative brain diseases. The company’s flagship software, Neurophet Aqua, uses AI to analyse brain MRI with the aim of identifying brain atrophy and white matter degeneration, both hallmarks of diseases including Alzheimer’s and vascular dementia. Neurophet claims its product can segment and examine brain images within five minutes with no analysis failure rate. The firm aims to enter Singapore’s $49bn valued medical industry, having first entered the market with its Neurophet Scale PET product, a tool that analyses biomarkers of Alzheimer’s disease. The tool combines brain PET and MRI images and also received HSA approval last year. The company is aiming to expand further into the Southeast Asian market through its work with Singapore’s Dementia Research Center. Neurophet is collaborating with the center to conduct multidisciplinary brain disease research that will validate the effectiveness of its AI software products. Last December, the company joined forces with medical device distributor Clairvo Technologies to expand the reach of Neurophet Aqua in Japan.


In a world where the number of people suffering from degenerative brain disorders is rapidly increasing, the development of innovative technology is essential for early diagnosis and management of these conditions. The approval of Neurophet’s AI brain degeneration analysis software by the Singaporean authorities marks a significant milestone in the fight against brain disorders. With its unparalleled accuracy and efficiency, the software has the potential to revolutionize the way medical professionals detect and diagnose brain conditions, leading to more effective treatments and improved patient outcomes. As we continue to harness the power of technology, we can look forward to a brighter future in the battle against these debilitating diseases.